A study of soft tissue sarcomas after childhood cancer in Britain

被引:19
作者
Jenkinson, H. C.
Winter, D. L.
Marsden, H. B.
Stovall, M. A.
Stevens, M. C. G.
Stiller, C. A.
Hawkins, M. M. [1 ]
机构
[1] Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England
[2] Birmingham Childrens Hosp, Dept Paediat Oncol, Birmingham B4 6NH, W Midlands, England
[3] Royal Manchester Childrens Hosp, Dept Paediat Pathol, Manchester M27 4HA, Lancs, England
[4] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[5] Univ Bristol, Inst Child Life & Hlth, Bristol BS2 8AE, Avon, England
[6] Univ Oxford, Dept Paediat, Childrens Canc Res Grp, Oxford OX2 6HJ, England
关键词
second soft tissue sarcoma; childhood cancer;
D O I
10.1038/sj.bjc.6603908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Among 16 541 3-year survivors of childhood cancer in Britain, 39 soft tissue sarcomas (STSs) occurred and 1.1 sarcomas were expected, yielding a standardised incidence ratio ( SIR) of 16.1. When retinoblastomas were excluded from the cohort, the SIR for STSs was 15.9, and the cumulative risk of developing a soft tissue tumour after childhood cancer within 20 years of 3-year survival was 0.23%. In the case-control study, there was a significant excess of STSs in those patients exposed to both radiotherapy (RT) and chemotherapy, which was five times that observed among those not exposed (P=0.02). On the basis of individual radiation dosimetry, there was evidence of a strong dose-response effect with a significant increase in the risk of STS with increasing dose of RT (P < 0.001). This effect remained significant in a multivariate model. The adjusted risk in patients exposed to RT doses of over 3000 cGy was over 50 times the risk in the unexposed. There was evidence of a dose-response effect with exposure to alkylating agents, the risk increasing substantially with increasing cumulative dose (P=0.05). This effect remained after adjusting for the effect of radiation exposure.
引用
收藏
页码:695 / 699
页数:5
相关论文
共 33 条
[1]  
[Anonymous], 1976, ICDO: International Classification of Diseases for Oncology
[2]   A CLASSIFICATION SCHEME FOR CHILDHOOD-CANCER [J].
BIRCH, JM ;
MARSDEN, HB .
INTERNATIONAL JOURNAL OF CANCER, 1987, 40 (05) :620-624
[3]  
BOICE JD, 1987, J NATL CANCER I, V79, P1295
[4]   2ND MALIGNANT NEOPLASMS FOLLOWING TREATMENT FOR WILMS-TUMOR - A REPORT FROM THE NATIONAL WILMS-TUMOR STUDY-GROUP [J].
BRESLOW, NE ;
TAKASHIMA, JR ;
WHITTON, JA ;
MOKSNESS, J ;
DANGIO, GJ ;
GREEN, DM .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1851-1859
[5]  
Breslow NE, 1980, STAT METHODS CANC RE, V1, DOI DOI 10.1097/00002030-199912240-00009
[6]  
Breslow NE, 1987, DESIGN ANAL COHORT S, V2
[7]   The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: Analysis of a series of 1524 cases consecutively treated at the Florence University Hospital [J].
Cellai, E ;
Magrini, SM ;
Masala, G ;
Alterini, R ;
Costantini, AS ;
Rigacci, L ;
Olmastroni, L ;
Papi, MG ;
Spediacci, MA ;
Innocenti, F ;
Bellesi, G ;
Ferrini, PR ;
Biti, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (05) :1327-1337
[8]   2ND PRIMARY NEOPLASMS IN PATIENTS WITH RETINOBLASTOMA [J].
DRAPER, GJ ;
SANDERS, BM ;
KINGSTON, JE .
BRITISH JOURNAL OF CANCER, 1986, 53 (05) :661-671
[9]   MORTALITY FROM 2ND TUMORS AMONG LONG-TERM SURVIVORS OF RETINOBLASTOMA [J].
ENG, C ;
LI, FP ;
ABRAMSON, DH ;
ELLSWORTH, RM ;
WONG, FL ;
GOLDMAN, MB ;
SEDDON, J ;
TARBELL, N ;
BOICE, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (14) :1121-1128
[10]   BREAST-CANCER AFTER TREATMENT OF HODGKINS-DISEASE [J].
HANCOCK, SL ;
TUCKER, MA ;
HOPPE, RT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (01) :25-31